[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337411-105":59,"doc-detail-337411-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","epha2-and-hdac-targeted-combination-therapy-in-endometrial-cancer","EphA2-and HDAC-Targeted Combination Therapy in Endometrial Cancer","","Endometrial cancer remains a leading malignant tumor of the female reproductive tract, yet lacks reliably effective therapies. EphA2, a receptor tyrosine kinase overexpressed in endometrial cancer, has shown only modest preclinical responses to EphA2-targeted drugs. High-throughput screening identified panobinostat, a histone deacetylase inhibitor, as a synergistic partner, supporting combination-driven cell death. The therapy enhanced DNA damage and apoptosis while reducing clonogenic survival in Ishikawa and Hec1A cells, and diminished tumor burden in mouse models. RNA sequencing indicated coordinated downregulation of cell survival programs, including senescence and cell-cycle regulators, alongside reduced Axl-PI3K-Akt-mTOR pathway activity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epha2-and-hdac-targeted-combination-therapy-in-endometrial-cancer/337411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epha2-and-hdac-targeted-combination-therapy-in-endometrial-cancer/337411.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is EphA2 considered a therapeutic target for endometrial cancer?","Question",{"text":113,"@type":114},"EphA2 is highly expressed in endometrial cancer and is linked to poor clinical outcomes. Evidence also supports EphA2’s roles in tumor growth and metastasis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does panobinostat play in the combination therapy?",{"text":118,"@type":114},"Panobinostat is identified through high-throughput drug screening as a candidate histone deacetylase inhibitor. The study hypothesizes it can synergize with an EphA2 inhibitor to increase therapeutic effect.",{"name":120,"@type":111,"acceptedAnswer":121},"What key biological effects does the combination therapy produce?",{"text":122,"@type":114},"The combination enhances DNA damage and increases apoptosis, while decreasing clonogenic survival in endometrial cancer cells. It also reduces tumor burden in mouse models and downregulates cell survival pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337411,1790621048,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Article  \nEphA2-and HDAC-Targeted Combination Therapy in Endometrial Cancer  \nRobiya Joseph 1,†, Santosh K. Dasari 1,†,‡, Sujanitha Umamaheswaran 1,2, Lingegowda S. Mangala 1,  \nEmine Bayraktar 1, Cristian Rodriguez-Aguayo 3, Yutuan Wu 1, Nghi Nguyen 4, Reid T. Powell 4, Mary Sobieski 4, Yuan Liu 1, Mark Seungwook Kim 1, Sara Corvigno 1, Katherine Foster 1, Pahul Hanjra 1,2, Thanh Chung Vu 1, Mamur A. Chowdhury 1, Paola Amero 3, Clifford Stephan 4, Gabriel Lopez-Berestein 3, Shannon N. Westin 1 and Anil K. Sood 1, *  \nCitation: Joseph, R.; Dasari, S.K.; Umamaheswaran, S.; Mangala, L.S.; Bayraktar, E.; Rodriguez-Aguayo, C.; Wu, Y.; Nguyen, N.; Powell, R.T.; Sobieski, M.; et al. EphA2-and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int. J. Mol. Sci. 2024, 25, 1278. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25021278](doi.org/10.3390/ijms25021278)  \nAcademic Editor: Laura Paleari  \nReceived: 2 December 2023  \nRevised: 5 January 2024  \nAccepted: 14 January 2024  \nPublished: 20 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [rjoseph7@mdanderson.org](rjoseph7@mdanderson.org) (R.J.); [santy2407@gmail.com](santy2407@gmail.com) (S.K.D.); [sumamaheswaran@mdanderson.org](sumamaheswaran@mdanderson.org) (S.U.); [lsmangala@mdanderson.org](lsmangala@mdanderson.org) (L.S.M.); [ebayraktar@mdanderson.org](ebayraktar@mdanderson.org) (E.B.); [wyutuandr@gmail.com](wyutuandr@gmail.com) (Y.W.); [yliu32@mdanderson.org](yliu32@mdanderson.org) (Y.L.); [mkim3@mdanderson.org](mkim3@mdanderson.org) (M.S.K.); [scorvigno@mdanderson.org](scorvigno@mdanderson.org) (S.C.); [fosterki13@gmail.com](fosterki13@gmail.com) (K.F.); [phanjra@mdanderson.org](phanjra@mdanderson.org) (P.H.); [tvu9@mdanderson.org](tvu9@mdanderson.org) (T.C.V.); [mamur@utexas.edu](mamur@utexas.edu) (M.A.C.); [swestin@mdanderson.org](swestin@mdanderson.org) (S.N.W.)  \n2 UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n3 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [crodriguez2@mdanderson.org](crodriguez2@mdanderson.org) (C.R.-A.); [pamero@mdanderson.org](pamero@mdanderson.org) (P.A.); [glopez@mdanderson.org](glopez@mdanderson.org) (G.L.-B.)  \n4 High-Throughput Research and Screening Center, Center for Translational Cancer Research, Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, TX 77030, USA; [nnguyen@tamu.edu](nnguyen@tamu.edu) (N.N.); [repowell@tamu.edu](repowell@tamu.edu) (R.T.P.); [msobieski@tamu.edu](msobieski@tamu.edu) (M.S.); [cstephan@ibt.tamhsc.edu](cstephan@ibt.tamhsc.edu) (C.S.)  \n* Correspondence: [asood@mdanderson.org](asood@mdanderson.org); Tel.: +1-713-745-5266 † These authors contributed equally to this work.  \n‡ Current address: National Institute of Animal Biotechnology, Hyderabad 500029, India.  \nAbstract: Endometrial cancer is the most frequent malignant tumor of the female reproductive tract but lacks effective therapy. EphA2, a receptor tyrosine kinase, is overexpressed by various cancers including endometrial cancer and is associated with poor clinical outcomes. In preclinical models, EphA2-targeted drugs had modest efficacy. To discover potential synergistic partners for EphA2-targeted drugs, we performed a high-throughput drug screen and identified panobinostat, a histone deacetylase inhibitor, as a candidate. We hypothesized that combination therapy with an EphA2 inhibitor and panobinostat leads ","cbCaifVCDFTCtegg","https://ap.wps.com/l/cbCaifVCDFTCtegg","pdf",3623708,13,"English","# Abstract\n# Introduction","[{\"question\":\"Why is EphA2 considered a therapeutic target for endometrial cancer?\",\"answer\":\"EphA2 is highly expressed in endometrial cancer and is linked to poor clinical outcomes. Evidence also supports EphA2’s roles in tumor growth and metastasis.\"},{\"question\":\"What role does panobinostat play in the combination therapy?\",\"answer\":\"Panobinostat is identified through high-throughput drug screening as a candidate histone deacetylase inhibitor. The study hypothesizes it can synergize with an EphA2 inhibitor to increase therapeutic effect.\"},{\"question\":\"What key biological effects does the combination therapy produce?\",\"answer\":\"The combination enhances DNA damage and increases apoptosis, while decreasing clonogenic survival in endometrial cancer cells. It also reduces tumor burden in mouse models and downregulates cell survival pathways.\"}]","EphA2-and HDAC-Targeted Combination Therapy in Endometrial Cancer | PDF",1790019017,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/716c10992418e4822be669f84a96cd4d.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b762e3144e2af42ef222480deea8da3.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d23bb7f126dce0706fe289897f8d98b7.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c87d94d620d298c96bf63aadd89d5ce7.webp",980,1385]